Publications by authors named "Lu-Hui Zhuang"
Article Synopsis
- DEB-TACE, known for its steady drug release and low side effects, shows promising results when combined with radiofrequency ablation (RFA) for treating primary hepatocellular carcinoma (HCC).
- A study involving 76 patients aimed to assess the treatment's efficacy and survival outcomes, comparing those with untreated HCC (Group A) and hepatectomy patients (Group C).
- Results indicated similar treatment effectiveness between Groups A and C, with Group A showing lower liver enzyme levels and absence of operational-related deaths, suggesting DEB-TACE combined with RFA is a viable option for HCC management with potential benefits.